BioSpace News Archive

Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the fourth quarter and year ended December 31, 2021 and provided a corporate update.

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a business update.

iCAD, Inc., a global medical technology leader providing innovative cancer detection and therapy solutions, reported its financial and operating results for the three and 12 months ended December 31, 2021.

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced its fourth quarter and full year 2021 financial results and business highlights.

Angion Biomedica Corp., a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, announced participation in two upcoming investment conferences.

Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today announced that its Investigational New Drug Application (IND) for its lead candidate, DT-216, for the treatment of Friedreich ataxia (FA), was cleared by the U.S. Food and Drug Administration (FDA).

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel irreversible covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, reported fourth quarter and full year 2021 financial results and business highlights.

Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address serious diseases, such as NASH and obesity, today announced that management will be participating in a NASH discussion panel at the Cowen 42nd Annual Healthcare Conference.

Seer, Inc., a life sciences company commercializing a disruptive new platform for proteomics, reported financial results for the fourth quarter and full year ended December 31, 2021.

Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced that its Chief Executive Officer Nima Farzan will provide a company overview at the 42nd Annual Cowen Health Care Conference.